1. Home
  2. ANL vs ZVIA Comparison

ANL vs ZVIA Comparison

Compare ANL & ZVIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Adlai Nortye Ltd.

ANL

Adlai Nortye Ltd.

HOLD

Current Price

$11.54

Market Cap

731.6M

Sector

N/A

ML Signal

HOLD

Logo Zevia PBC

ZVIA

Zevia PBC

BUY

Current Price

$1.60

Market Cap

96.4M

ML Signal

BUY

Company Overview

Basic Information
Metric
ANL
ZVIA
Founded
2004
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Beverages (Production/Distribution)
Sector
Consumer Staples
Exchange
Nasdaq
Nasdaq
Market Cap
731.6M
96.4M
IPO Year
2022
2021

Fundamental Metrics

Financial Performance
Metric
ANL
ZVIA
Price
$11.54
$1.60
Analyst Decision
Strong Buy
Buy
Analyst Count
1
4
Target Price
$20.00
$4.93
AVG Volume (30 Days)
208.2K
1.1M
Earning Date
04-10-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
55.88
EPS
N/A
N/A
Revenue
N/A
$161,259,000.00
Revenue This Year
$36.02
$8.30
Revenue Next Year
N/A
$6.87
P/E Ratio
N/A
N/A
Revenue Growth
N/A
4.01
52 Week Low
$0.88
$1.11
52 Week High
$17.25
$3.66

Technical Indicators

Market Signals
Indicator
ANL
ZVIA
Relative Strength Index (RSI) 44.65 57.02
Support Level $6.92 $1.13
Resistance Level $12.09 $2.71
Average True Range (ATR) 1.33 0.16
MACD -0.33 0.04
Stochastic Oscillator 21.53 55.35

Price Performance

Historical Comparison
ANL
ZVIA

About ANL Adlai Nortye Ltd.

Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.

About ZVIA Zevia PBC

Zevia PBC is a beverage company disrupting the liquid refreshment beverage industry through refreshing, zero-calorie, zero-sugar, naturally sweetened beverages that are all Non-GMO Project Verified. It offers a platform of products that include a variety of flavors across Soda, Energy Drinks, Organic Tea, Mixers, Kidz drinks, and Sparkling Water. Its products are distributed across the U.S. and Canada through a network of retailers in the food, drug, mass, natural, and e-commerce channels. The company derives a majority of its revenue from the United States.

Share on Social Networks: